Executive Interview with the Guerbet CEO David Hale on ‘innovation4MRI’

David Hale, CEO, Guerbet

How is Guerbet innovating in MRI contrast media and associated technologies?

David: Guerbet is a pioneer with a long history – over 100 years in the field of contrast agents, particularly in MRI, having invented the 1st macrocyclic GBCA, which has been on the market for more than 30 years and in more than 70 countries.

This really gives us the opportunity to build very strong relationships with the radiology community and through that better understand their medical needs.

We’re a company with a long-term growth strategy supported by shareholders from the Guerbet family and we invest a significant part of our revenues 10% in R&D (Research & Development). With more than 200 of our employees are dedicated to innovation in 5 R&D centers around the world. They’re actively collaborate with a broad network of academic partners, centers of excellence to strengthen and accelerate our innovation capabilities.

Guerbet’s innovation in MRI is not restricted to the development of contrast agents and injection systems. We’re also actively exploring new approaches in MRI, including the integration of artificial intelligence (AI), this is a way to the future of clinical imaging.

What were Guerbet’s guiding principles over the decades to foster relationships with clients and partners?

At the basis our guiding principle (and this is also our purpose) has really been – can we build a lasting relationship to do something together that enables people to live better. At Guerbet we relentless in our commitment to go further and to help build the future of medical imaging.

Collaborating closely with radiological community, observing and listening, sharing knowledge through multiple educational resources – that allows us to better anticipate what their needs are for patients. And I would add that what makes us unique ‘Guerbet touch’ is with nearly a century of passion and dedication to innovation. This is the commitment that drives our R&D teams to create innovations that serve both radiologists and patients.

How do you see Guerbet’s contribution to the future of medical imaging?

Guerbet will obviously continue to invest in R&D specifically focused on helping our radiologists, delivering on their expectations in their daily practice and help them improve on patient outcomes.

If you think about it, given the ever-increasing volume of information that radiologists are expected to be aware of, about best practices and new techniques in the field of MRI.

For us it seems fairly obvious for us to provide what help we can in this area. Guerbet is committed to staying at the forefront of innovation in MRI and as a leader in the field we believe by sharing information and building new solutions, we can really add value.

We’re specifically focused on working on innovation that will improve the radiology practice and benefit patients. One area of innovation is ‘how do we find solutions to reduce gadolinium retention in both in patients and in the environment’. The is an emerging unmet need and in this are Guerbet primarily position to help

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. A world leader in medical imaging, Guerbet is a publicly traded company on the Euronext Paris Stock Exchange, headquartered in France with offices and production facilities in Europe, the Americas and Asia-Pacific. It has a long-standing reputation as a pioneer in the research and development of contrast media for radiology.

Today, Guerbet contributes to progress made in the diagnosis of major disease areas including cancer, cardiovascular, inflammatory and neurodegenerative diseases. The company’s novel and effective imaging solutions help to improve patient management throughout the world. Guerbet offers a comprehensive range of imaging products, solutions, and services for Diagnostic Imaging –MRI, X Ray, Digital Solutions / AI– and Interventional Imaging, to enhance clinical decision-making, from diagnosis to treatment and follow-up, and improve patients’ quality of life.

For more information, please visit www.guerbet.com.

About Innovation4MRI

Innovation4MRI.com has been created to provide a source of relevant news about innovation in MRI. The information published on the site has been selected and reviewed for relevance, interest, and outstanding scientific value. The site provides information about 3 pillars of innovation in MRI: scanners (hardware) and image analysis and digital capabilities (software), image-enhancement approaches (including contrast agents), and sustainability (packaging).

Innovation4MRI.com provides summaries and links to research articles, recent reviews, public presentations, and video or podcast interviews with experts. These include interviews with academics and clinicians with expertise in radiology, as well as experts working in private industry. All the resources on the site have been carefully selected because they are particularly relevant to MRI enthusiasts.

--Issue 57--

Author Bio

David Hale

David Hale was appointed Chief Executive Officer of Guerbet on January 1, 2020. He joined Guerbet Executive Committee as Chief Commercial Officer in February 2018. David has almost twenty years’ experience in the field of radiology. His international career is characterised by strong geographical mobility, particularly in the United States, France, Germany and Switzerland, contributing to his ability to adapt and succeed in different cultures.

Latest Issue
Get instant
access to our latest e-book
Sanofi Dubai Derma 2023